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Maurizio Bonati1* and Antonio Clavenna2Keywords: Influenza vaccines, Vaccination, Newborn, InfantSeasonal influenza is an important public health and
medical challenge. Vaccination against influenza is recog-
nized worldwide as the main strategy for prevention and
control. The findings of meta-analyses, however, suggest
that efficacy and effectiveness of influenza vaccines, both
in people aged 65 years or older [1] and in children, are
lower than believed [2]. These findings were recently con-
firmed, even if mitigated (only) a little, by an additional
meta-analysis. This recent study assessed efficacy and ef-
fectiveness of licensed influenza vaccines in the USA with
sensitive and highly specific diagnostic tests used to con-
firm influenza [3]. Findings show that in healthy children
influenza vaccines have a very variable efficacy (vaccine
effects on lab-confirmed influenza) and effectiveness (pre-
vention of influenza-like illness). Available safety data are
scant, particularly for inactivated vaccines in younger chil-
dren [2]. In such a context, when the seasonal periods for
influenza arrive, questions concerning who should receive
the influenza vaccine are raised among health operators
and lay people worldwide. Pediatricians, parents, and
caregivers of infants and children in particular, are doubt-
ful as to whether to recommend or accept influenza
immunization of children or not [4], also because in chil-
dren the infection is usually self-limiting without compli-
cations, though the risk is higher in those aged less than
6 months [5].
In 2010, the Advisory Committee on Immunization
Practices (ACIP) established the first recommendation
for a national, universal seasonal influenza vaccination
in the USA [6].
Vaccination every year is recommended by ACIP with
trivalent inactivated vaccine (TIV) for all individuals
aged 6 months or older, or with live attenuated influenza
vaccine (LAIV) for healthy, non-pregnant people aged
2-49 years. Up until now only a few countries (i.e.,* Correspondence: mother_child@marionegri.it
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distribution, and reproduction in any mediumAustria, Canada, and Estonia) universally recommend
the seasonal influenza vaccination. The majority of
countries continues to apply, for the paediatric popula-
tion, the World Health Organization recommendations
that suggest vaccinating only children older than 6
months of age with certain coexisting conditions
(chronic heart or lung diseases, metabolic or renal dis-
eases, chronic neurological conditions, or immunodefi-
ciencies) through strategies that involve an active
promotion of the vaccine [7]. Household contacts of
those children are unfortunately not considered, al-
though individual member states may consider influenza
vaccination programs that target all persons 6 months of
age and older if feasible and cost-effective.
This is the public health context, in which national and
regional decisions are the result of prevailing evaluations
often characterized by a balancing of, and mediation be-
tween, evidence based knowledge, available public funds,
health system organization, as well as historical legacies
and inertia, policy lock-in, and unchecked assumptions
about the benefit of influenza vaccines.
Scant data are available concerning the incidence of
influenza in the pediatric population. A meta-analysis of
24 epidemiological studies monitoring different influ-
enza seasons estimated an annual incidence in children
less than 5 years old of 5.6% (95%CI 2.8 to 10.6%) in the
developed countries and of 15.0% (95%CI 9.8 to 22.9%)
in developing countries [5]. The incidence in developed
countries decreased to 3.0% (0.9, 10.0%) when only study
using polymerase chain reaction as diagnostic tool were
taken into account [5].
The average annual rate of hospitalization associated
with influenza is reported in developed countries as ran-
ging from 0.6 to 2.7 per 1000 children younger than 5
years of age [8,9], whereas the average annual rates of
outpatient visits attributable to influenza are 10-250 times
as high as hospitalization rates, and increase with age [8].
This wide variability in estimates is attributable to dif-
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tion surveyed, definition of influenza season, study de-
sign and objectives.
Such a weakly defined epidemiological profile coin-
cides with the lack of hard evidence on efficacy and ef-
fectiveness of influenza immunization in children
because the same limitations are present in clinical trials,
with even further variability attributable to laboratory
tests, vaccines used, etc.
Public health decisions and recommendations are con-
sequently not only complex in and of themselves, but
are also difficult in such a scenario.
Ongoing research in the field (much of which is indus-
try sponsored) is waiting for a new generation of more
effective, cross-protective influenza vaccines and is, in
the meantime, oriented towards defining the efficacy in
children of influenza vaccines that are used in adults.
The TIV vaccine has currently been shown an efficacy
(prevention of confirmed influenza) of 59% and an ef-
fectiveness (prevention of influenza-like illness) of 36%
in children older than 2 years of age [2], whereas the
intranasal LAIV has been shown to have a greater effi-
cacy (69.2-95.6%) only in children 2-7 years of age, but
cannot be used in children under 2 years of age because
of an increased risk of hospitalization [10].
At present, children aged 6-72 months are the favorite
population of influenza vaccine studies to show a super-
ior protective efficacy of adjuvant TIV vaccines [11].
The question, however, remains. Should infants be
vaccinated against seasonal influenza? Currently, this
vaccination is not recommended in any country for
healthy, preterm, or low birth weight infants, even if
they have chronic diseases that are contemplated by
immunization strategies for infants older than 6 months.
Moreover, it is important to underline that influenza
vaccines up to date have not been approved by regula-
tors for use in infants.
Due to the immature or impaired cellular and humoral
immune systems and the presence of maternal anti-
bodies at protective levels in babies, in several countries
vaccines are routinely recommended from 2 months of
age, also for preterm and low birth weight infants
[12,13]. The only exception is the vaccination against
hepatitis B for all at risk newborns, in particular those
born to mothers HBsAG positive, who should receive
the vaccine within 12-24 hours after birth, regardless of
gestational age or birth weight [12,14].
Although the risk of severe influenza infection and
the rate of hospitalization are higher in infants during
their first 6 months of life than in older infants [8], in
particular in those born to mothers who have not been
exposed to the virus [15], there are only 4 published
studies on inactivated influenza vaccination in infants
under 6 months [16-19].In the first study, 62 infants 3 to 5 months of age with
bronchopulmonary dysplasia or congenital heart disease
were vaccinated using four different TIV vaccines [16].
In the second study, 42 healthy infants aged 10-22 weeks
received two different TIV vaccines [17]. In the third,
126 infants 2-3 months of age were randomized to re-
ceive a TIV vaccine either via the intramuscular or intra-
dermal route [18]. The findings of the first two studies
demonstrated seroconversion only in the range of 0-55%
against the various vaccine-contained antigens with a
suggested age related trend, whereas the extremely high
percentage of maternal antibodies at protective levels in
the infants in the third study precluded the testing of
immunogenicity in this age group (only 4 out of 126
infants had hemagglutination inhibition titer <40 against
at least one vaccine-covered antigen before vaccination)
[18].
In a large randomized placebo controlled trial evaluat-
ing the antibody titers in 1304 subjects 6-12 weeks of
age, 90.2% of TIV recipients achieved potential seropro-
tection to at least one influenza strain following the sec-
ond vaccine dose [19]. Seroprotection rates differed
from 10.9 to 85.6% among individual vaccine antigens.
Safety profiles were similar in the TIV and placebo
groups [19].
All these studies were mainly focused on the evalu-
ation of immunogenicity. None of them was designed
for evaluating clinical or public health endpoints.
In the past a few studies were performed to evaluate
the immunogenicity of LAIV vaccines in infants under 6
months [2,20,21]. The rate of seroconversion was similar
to that observed with TIV vaccines, but a higher rate of
adverse effects was reported with LAIV vaccines in chil-
dren under 2 years of age [10].
Without evidence suggesting benefit outweights harms
at either the individual or societal (public health) level,
today, any attempt to suggest immunizing infants less
than 6 months of age against seasonal influenza would
be off-label, arbitrary and unethical. Off-label use of
drugs and vaccines is legal since regulatory agencies do
not regulate the practice of medicine but, either way, it
should be evidence-based. Public health solutions using
current influenza vaccines are difficult to imagine be-
cause of the wide methodological differences between
the performed studies; the interseasonal variation and
the everchanging antigenicity of the influenza virus; the
variation in efficacy and effectiveness (risk reduction in
populations offered the vaccine) by total vaccine cover-
age and degree of herd immunity for each season.
However, infants younger than 6 months are also a
reservoir for potential child-to-adult transmission and
other effective preventive and treatment strategies for
these infants alternative to influenza vaccines should be
fully evaluated. The high maternal antibody levels
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agreement with the results of investigations showing that
the vaccine is safe and effective in protecting pregnant
women and their infants for a few months after birth
[22]. 45-65% of influenza disease in infants is prevent-
able through maternal immunization programmes [23].
In 2005, the WHO was already recommending influenza
vaccination for all pregnant women during the influenza
season [24]. Although new evidences supports the effi-
cacy and the effectiveness of influenza vaccine adminis-
tration during pregnancy in exposed women and their
newborn babies [25,26], and safety data suggest inacti-
vated vaccines for seasonal influenza are safe in preg-
nancy [27,28], vaccination is underused in pregnancy
[29].
Concerning the passive immunization, or indirect pro-
tection, of a newborn, the breast milk-mediated protec-
tion against respiratory viruses is well established [30],
as the role of brestfeeding in infants infected with influ-
enza virus [31], thus promoting exclusive breastfeeding
also against infectious diseases should be kept in mind
[32,33]. Therefore, while waiting for safe, effective and
affordable vaccines for infants, this population can also
be protected by limiting their exposure to influenza
through both educational interventions (including hand
washing) [6,34,35] targeting health care workers [36],
family members, caregivers, and all individuals who res-
ide with newborns, in particular ill ones [35]. Moreover,
some benefits may be obtained by applying “cocoon”
immunization strategies immunizing all individuals who
come into contact with infants, as suggested by uncon-
trolled studies [37].
In conclusion, seasonal influenza is a major public
health issue at the extremes of ages and in susceptible
groups. Until an effective influenza vaccine is achievable,
more evidence about both efficacy of flu immunization
in early infants and alternative interventions to influenza
vaccination is available, and preventive strategies imple-
mented, it would be more important to improve the
coverage in higher risk children than to enlarge the
immunization age range of healthy children.
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